Review



got1 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech got1 antibody
    Got1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/pm41478064-46-5-7
    Average 93 stars, based on 52 article reviews
    got1 antibody - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Saline:

    Article Title: A glutamine metabolism-related gene signature for liver fibrosis prediction integrating single-cell and bulk transcriptomic analysis with multi-cohort validation
    Article Snippet: Equal amounts of protein (30 μg per lane) were separated by SDS-PAGE on 10% polyacrylamide gels and transferred onto PVDF membranes (Millipore, USA). .. Membranes were blocked with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20) at room temperature for 1 hour, then incubated overnight at 4°C with primary antibodies: anti-GOT1 (Proteintech, Cat No. 14886-1-AP, diluted 1:1000), anti-GLS (Proteintech, Cat No. 12855-1-AP, diluted 1:5000), and anti-β-actin (Abiowell, Cat No. AWA80113, diluted 1:5000). ..

    Incubation:

    Article Title: A glutamine metabolism-related gene signature for liver fibrosis prediction integrating single-cell and bulk transcriptomic analysis with multi-cohort validation
    Article Snippet: Equal amounts of protein (30 μg per lane) were separated by SDS-PAGE on 10% polyacrylamide gels and transferred onto PVDF membranes (Millipore, USA). .. Membranes were blocked with 5% non-fat milk in TBST (Tris-buffered saline with 0.1% Tween-20) at room temperature for 1 hour, then incubated overnight at 4°C with primary antibodies: anti-GOT1 (Proteintech, Cat No. 14886-1-AP, diluted 1:1000), anti-GLS (Proteintech, Cat No. 12855-1-AP, diluted 1:5000), and anti-β-actin (Abiowell, Cat No. AWA80113, diluted 1:5000). ..

    Article Title: Radiotherapy followed by metformin neoadjuvant therapy drives superior pancreatic cancer ferroptosis and augments anti-tumor immunity
    Article Snippet: .. After deparaffinization nd antigen retrieval in citrate buffer, sections were permeabilized with .3% Triton X-100, blocked with 5% BSA, and incubated overnight at °C with primary antibodies: anti-rabbit Ki-67 (Proteintech, #28074-1- P) and anti-mouse GOT1 (Proteintech, #60317-1-Ig). ..

    Article Title: Radiotherapy followed by metformin neoadjuvant therapy drives superior pancreatic cancer ferroptosis and augments anti-tumor immunity
    Article Snippet: .. Sections were subsequently dewaxed and then incubated ith anti-human GOT1 (Proteintech, #14886-1-AP), anti-mouse GOT1 Proteintech, #60317-1-Ig), and anti-mouse CD8 (Proteintech, #66868- -Ig), and anti-mouse CD11c (Abclonal, #A1508), respectively, at °C overnight. .. After being stained with hematoxylin, the sections were s c h a 0 4 A A l r 2 S 1 t 2 f s d i e t b f P v 2 s w y S t t 0 a s 3 3 a e c p c t M t c e ( p a b r r i o [ l P c t a R e c 1 o m & ( R t R i ( P t m c e t a w c w t t f 3 n t s p i c y a m f ( M t p p i a i P a p c e ealed with neutral resin, scanned and analyzed under an Olympus miroscope.

    other:

    Article Title: Aspartate availability drives differential engagement of the malate-aspartate shuttle.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Recombinant DNA lentiCRISPR v2 Sanjana et al. 69 Addgene Plasmid #52961 pUC57-LbNOX Titov et al. 29 Addgene Plasmid #75285 N174-MCS Adam Karpf Addgene Plasmid #81061 GpASNase1 Sullivan et al. 38 Addgene Plasmid #121526 pCW57-GFP-P2A-MCS (Neo) Barger et al. 70 Addgene Plasmid #89181 psPAX2 Didier Trono Addgene Plasmid #12260 pMD2.G Didier Trono Addgene Plasmid #12259 pCW57-GFP-P2A-ByASPase This paper Addgene Plasmid #252094 pCW57-GFP-P2A-EcASPase This paper Addgene Plasmid #252079 Software and algorithms R Cran https://www.r-project.org Prism 9-10 Graphpad https://www.graphpad.com IsoCor v2.0 Millard et al. 71 N/A Quant Studio 5-6 Thermo Fisher Scientific https://www.thermofisher.com/us/en/ home/life-science/pcr/real-time-pcr/realtime-pcr-instruments/quantstudiosystems/features.html#design-andanalysis-software MassHunter Agilent https://www.agilent.com/en/product/ software-informatics/mass-spectrometrysoftware/data-analysis Wave Desktop Agilent https://www.agilent.com/en/product/cell- analysis/real-time-cell-metabolic-analysis/ xf-software/seahorse-wave-desktopsoftware-740897?srsltid=AfmBOoojwqu EuqNM6xcIjeIHptR1Aj2AEeiKGlha32Itn1iQsuyp1LH e3 Molecular Cell 86, 954–967.e1–e7, March 5, 2026

    Recombinant:

    Article Title: Aspartate availability drives differential engagement of the malate-aspartate shuttle.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse IgG HRP Linked Whole Ab Sigma-Aldrich/Cytiva Cat#GENA931-1ML Rabbit IgG HRP Linked Whole Ab Sigma-Aldrich/Cytiva Cat#GENA934-1ML; RRID: AB_2722659 MDH1 Polyclonal antibody Proteintech Cat15904-1-AP; RRID: AB_2143279 SLC25A11 Polyclonal antibody Proteintech Cat#12253-1-AP; RRID: AB_2877840 GOT1 Polyclonal antibody Proteintech Cat#14886-1-AP; RRID: AB_2113630 ARALAR/AGC1 (D5I6I) Rabbit Monoclonal Antibody Cell Signaling Technology Cat#64169S; RRID: AB_2799655 SLC25A13 Polyclonal Antibody Invitrogen Cat#PA5-21991; RRID: AB_11153758 GOT2 Polyclonal antibody Proteintech Cat#14800-1-AP; RRID: AB_2247898 Anti-MDH2 antibody Abcam Cat#ab96193; RRID: AB_10679348 ANTI-FLAG M2 antibody, Mouse monoclonal Sigma-Aldrich Cat#F1804; RRID: AB_262044 Anti-Vinculin Antibody Sigma-Aldrich Cat#V9131; RRID: AB_477629 Chemicals, peptides, and recombinant proteins DMSO Sigma-Aldrich Cat#D2650-100ML Puromycin Dihydrochloride ThermoFisher Scientific/Gibco Cat#A1113803 G418 Sulfate Solution GeminiBio Cat#400-113 Doxycycline hyclate Sigma-Aldrich Cat#D9891 Hexadimethrine bromide (polybrene) Sigma-Aldrich Cat#107689 RPMI MSKCC media core N/A DMEM, high glucose MSKCC media core N/A DMEM:F-12 MSKCC media core N/A L-Glutamine MSKCC media core N/A RPMI, minus glucose minus glutamine MSKCC media core N/A DMEM, high glucose, minus serine, minus glycine MSKCC media core N/A BenchMarkTM Fetal Bovine Serum Gemini Bio Cat#100-106 Dialyzed Fetal Bovine Serum Gemini Bio Cat#100-108-500 DMEM, no glucose, no glutamine, no phenol red Gibco Cat#A1443001 D-(+)-Glucose solution 45% Corning Cat#45001-116 Horse Serum, heat inactivated, New Zealand origin ThermoFisher Scientific/Gibco Cat#26050070 RIPA Buffer (10x) Cell Signaling Technologies Cat#9806 3-Isobutyl-1-methylxanthine Sigma-Aldrich Cat#I5879 Dexamethasone Sigma-Aldrich Cat#D8893 Troglitazone Sigma-Aldrich Cat#T2573 Insulin human Sigma-Aldrich Cat#I3536 Linoleic Acid-Oleic Acid-Albumin, 100x Sigma-Aldrich Cat#L9655 Pyridine Thermo Fisher Scientific Cat#TS-27530 Methoxyamine hydrochloride Sigma-Aldrich Cat#226904 Thermo ScientificTM MSTFA Thermo Fisher Scientific Cat#PI48910 Methanol, OptimaTM for HPLC, Fisher ChemicalTM Fisher Scientific Cat#A454SK-4 (Continued on next page) e1 Molecular Cell 86, 954–967.e1–e7, March 5, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Ethyl acetate, ACS, 99.5+% Fisher Scientific Cat#AA31344M1 Nutlin-3a Selleckchem Cat#S8059 Etoposide Sigma-Aldrich Cat#E1383 Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) Sigma-Aldrich Cat#C2920 Sodium Pyruvate (100 mM) Gibco Cat#11360070 TRIzolTM Reagent Invitrogen Cat#15596018 Power SYBRTM Green PCR Master Mix Applied Biosystems Cat#4367659 L-Asparagine monohydrate Sigma-Aldrich Cat#A7094 L-Serine Sigma-Aldrich Cat#S4311 Glycine Sigma-Aldrich Cat#50046 L-Glutamic acid monosodium salt monohydrate Sigma-Aldrich Cat#49621 N-Acetyl-L-cysteine Sigma-Aldrich Cat#A9165 Oil Red O solution Sigma-Aldrich Cat#O1391 X-Gal Roche Cat#10651745001 D-Glucose (U-1 3 C6, 99%) Cambridge Isotopes Laboratories, Inc. Cat#CLM-1396-10 L-Glutamine (1 3 C5, 99%) Cambridge Isotopes Laboratories, Inc. Cat#CLM-1822-H-1 PierceTM ECL Western Blotting Substrate Thermo Fisher Scientific Cat#32106 Critical commercial assays PierceTM BCA Protein Assay Kits Thermo Fisher Scientific Cat#23225 Seahorse XF Cell Mito Stress Test Kit Agilent Cat#103015-100 iScriptTM cDNA Synthesis Kit Biorad Cat#1708891 QIAGEN Plasmid Maxi Kit Qiagen Cat#12163 QIAGEN Plasmid Mini Kit Qiagen Cat#12125 QIAquick PCR & Gel Cleanup Kit Qiagen Cat#28506 QIAEX II Gel Extraction Kit Qiagen Cat#20051 Deposited data DepMap Portal R23Q4 Broad; Arafeh et al. 65 https://depmap.org/portal Original uncropped western blots This paper Mendeley Data: https://doi.org/10.17632/ k43x8thkyn.2 Experimental models: Cell lines C3H/10T1/2, Clone 8 ATCC Cat#CCL-226 C2C12 ATCC Cat#CRL-1772 293T ATCC Cat#CRL-3216 A549 ATCC Cat#CRM-CCL-185 SW872 ATCC Cat#HTB-92 Calu1 ATCC Cat#HTB-54 NCI-H1975 ATCC Cat#CRL-5908 NCI-H2122 ATCC Cat#CRL-5985 NCI-H2170 ATCC Cat#CRL-5928 NCI-H1993 ATCC Cat#CRL-5909 Oligonucleotides Guide RNAs for metabolic enzymes (STAR Methods) This paper and Morris et al. 66 and Wang et al. 67 IDT qPCR primers (STAR Methods) This paper and Lercher et al. 68 IDT Codon optimized ASPases (STAR Methods) This paper Twist Bioscience (Continued on next page) Molecular Cell 86, 954–967.e1–e7, March 5, 2026 e2

    High Performance Liquid Chromatography:

    Article Title: Aspartate availability drives differential engagement of the malate-aspartate shuttle.
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse IgG HRP Linked Whole Ab Sigma-Aldrich/Cytiva Cat#GENA931-1ML Rabbit IgG HRP Linked Whole Ab Sigma-Aldrich/Cytiva Cat#GENA934-1ML; RRID: AB_2722659 MDH1 Polyclonal antibody Proteintech Cat15904-1-AP; RRID: AB_2143279 SLC25A11 Polyclonal antibody Proteintech Cat#12253-1-AP; RRID: AB_2877840 GOT1 Polyclonal antibody Proteintech Cat#14886-1-AP; RRID: AB_2113630 ARALAR/AGC1 (D5I6I) Rabbit Monoclonal Antibody Cell Signaling Technology Cat#64169S; RRID: AB_2799655 SLC25A13 Polyclonal Antibody Invitrogen Cat#PA5-21991; RRID: AB_11153758 GOT2 Polyclonal antibody Proteintech Cat#14800-1-AP; RRID: AB_2247898 Anti-MDH2 antibody Abcam Cat#ab96193; RRID: AB_10679348 ANTI-FLAG M2 antibody, Mouse monoclonal Sigma-Aldrich Cat#F1804; RRID: AB_262044 Anti-Vinculin Antibody Sigma-Aldrich Cat#V9131; RRID: AB_477629 Chemicals, peptides, and recombinant proteins DMSO Sigma-Aldrich Cat#D2650-100ML Puromycin Dihydrochloride ThermoFisher Scientific/Gibco Cat#A1113803 G418 Sulfate Solution GeminiBio Cat#400-113 Doxycycline hyclate Sigma-Aldrich Cat#D9891 Hexadimethrine bromide (polybrene) Sigma-Aldrich Cat#107689 RPMI MSKCC media core N/A DMEM, high glucose MSKCC media core N/A DMEM:F-12 MSKCC media core N/A L-Glutamine MSKCC media core N/A RPMI, minus glucose minus glutamine MSKCC media core N/A DMEM, high glucose, minus serine, minus glycine MSKCC media core N/A BenchMarkTM Fetal Bovine Serum Gemini Bio Cat#100-106 Dialyzed Fetal Bovine Serum Gemini Bio Cat#100-108-500 DMEM, no glucose, no glutamine, no phenol red Gibco Cat#A1443001 D-(+)-Glucose solution 45% Corning Cat#45001-116 Horse Serum, heat inactivated, New Zealand origin ThermoFisher Scientific/Gibco Cat#26050070 RIPA Buffer (10x) Cell Signaling Technologies Cat#9806 3-Isobutyl-1-methylxanthine Sigma-Aldrich Cat#I5879 Dexamethasone Sigma-Aldrich Cat#D8893 Troglitazone Sigma-Aldrich Cat#T2573 Insulin human Sigma-Aldrich Cat#I3536 Linoleic Acid-Oleic Acid-Albumin, 100x Sigma-Aldrich Cat#L9655 Pyridine Thermo Fisher Scientific Cat#TS-27530 Methoxyamine hydrochloride Sigma-Aldrich Cat#226904 Thermo ScientificTM MSTFA Thermo Fisher Scientific Cat#PI48910 Methanol, OptimaTM for HPLC, Fisher ChemicalTM Fisher Scientific Cat#A454SK-4 (Continued on next page) e1 Molecular Cell 86, 954–967.e1–e7, March 5, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Ethyl acetate, ACS, 99.5+% Fisher Scientific Cat#AA31344M1 Nutlin-3a Selleckchem Cat#S8059 Etoposide Sigma-Aldrich Cat#E1383 Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) Sigma-Aldrich Cat#C2920 Sodium Pyruvate (100 mM) Gibco Cat#11360070 TRIzolTM Reagent Invitrogen Cat#15596018 Power SYBRTM Green PCR Master Mix Applied Biosystems Cat#4367659 L-Asparagine monohydrate Sigma-Aldrich Cat#A7094 L-Serine Sigma-Aldrich Cat#S4311 Glycine Sigma-Aldrich Cat#50046 L-Glutamic acid monosodium salt monohydrate Sigma-Aldrich Cat#49621 N-Acetyl-L-cysteine Sigma-Aldrich Cat#A9165 Oil Red O solution Sigma-Aldrich Cat#O1391 X-Gal Roche Cat#10651745001 D-Glucose (U-1 3 C6, 99%) Cambridge Isotopes Laboratories, Inc. Cat#CLM-1396-10 L-Glutamine (1 3 C5, 99%) Cambridge Isotopes Laboratories, Inc. Cat#CLM-1822-H-1 PierceTM ECL Western Blotting Substrate Thermo Fisher Scientific Cat#32106 Critical commercial assays PierceTM BCA Protein Assay Kits Thermo Fisher Scientific Cat#23225 Seahorse XF Cell Mito Stress Test Kit Agilent Cat#103015-100 iScriptTM cDNA Synthesis Kit Biorad Cat#1708891 QIAGEN Plasmid Maxi Kit Qiagen Cat#12163 QIAGEN Plasmid Mini Kit Qiagen Cat#12125 QIAquick PCR & Gel Cleanup Kit Qiagen Cat#28506 QIAEX II Gel Extraction Kit Qiagen Cat#20051 Deposited data DepMap Portal R23Q4 Broad; Arafeh et al. 65 https://depmap.org/portal Original uncropped western blots This paper Mendeley Data: https://doi.org/10.17632/ k43x8thkyn.2 Experimental models: Cell lines C3H/10T1/2, Clone 8 ATCC Cat#CCL-226 C2C12 ATCC Cat#CRL-1772 293T ATCC Cat#CRL-3216 A549 ATCC Cat#CRM-CCL-185 SW872 ATCC Cat#HTB-92 Calu1 ATCC Cat#HTB-54 NCI-H1975 ATCC Cat#CRL-5908 NCI-H2122 ATCC Cat#CRL-5985 NCI-H2170 ATCC Cat#CRL-5928 NCI-H1993 ATCC Cat#CRL-5909 Oligonucleotides Guide RNAs for metabolic enzymes (STAR Methods) This paper and Morris et al. 66 and Wang et al. 67 IDT qPCR primers (STAR Methods) This paper and Lercher et al. 68 IDT Codon optimized ASPases (STAR Methods) This paper Twist Bioscience (Continued on next page) Molecular Cell 86, 954–967.e1–e7, March 5, 2026 e2



    Similar Products

    94
    MedChemExpress got1 inhibitor
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Got1 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+inhibitor-1/pmc12955881-68-21-23
    Average 94 stars, based on 1 article reviews
    got1 inhibitor - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Proteintech anti got1
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Anti Got1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/10__1038_slash_s41598___026___69198___8-119-28-29
    Average 93 stars, based on 1 article reviews
    anti got1 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology partial protein fragment
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Partial Protein Fragment, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Rabbit+pAb/pm42236942-626-10-32
    Average 94 stars, based on 1 article reviews
    partial protein fragment - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Shanghai Genechem Ltd lentivirus expressing shrna targeting got1
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Lentivirus Expressing Shrna Targeting Got1, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/expressing+got1+lentivirus+shrna+targeting/10__1186_slash_s40001___026___04271___6-83-6-21
    Average 86 stars, based on 1 article reviews
    lentivirus expressing shrna targeting got1 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology membranes
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    Membranes, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Rabbit+pAb/pm41892305-141-1-13
    Average 94 stars, based on 1 article reviews
    membranes - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Proteintech 1 ap
    Effects of <t>GOT1</t> inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.
    1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/pm41759528-264-35-34
    Average 93 stars, based on 1 article reviews
    1 ap - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology got1
    TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes <t>(GOT1,</t> GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)
    Got1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Rabbit+pAb/pmc13077985-74-8-9
    Average 94 stars, based on 1 article reviews
    got1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Proteintech got1
    TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes <t>(GOT1,</t> GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)
    Got1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/got1/GOT1+Antibody/pm41760625-326-50-52
    Average 93 stars, based on 1 article reviews
    got1 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Effects of GOT1 inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.

    Journal: Advanced Science

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    doi: 10.1002/advs.202516578

    Figure Lengend Snippet: Effects of GOT1 inhibition in the pancreatic TME. (a) Schematic of glutamine metabolism. (b) Determination of half‐maximal inhibitory concentration (IC 50 ) of the GOT1 inhibitor using mono‐ and multicellular 3D cultures. (c) Cell viability of mono‐ and multicellular 3D cultures. n = 3, **** = p ≤ 0.0001, (d) live/dead staining (scale bar = 100 µm), and (e) relative metabolite quantification following GOT1 inhibition. (f) Gene ontology enrichment analysis, and (g) volcano plot showing the significantly up/downregulated matrisome proteins of treated versus non‐treated multicellular 3D cultures. Blue = upregulated, red = downregulated. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. (h) Immunoblot of multicellular 3D cultures upon GOT1 inhibition. (i) Cell metabolic activity for PDAC cells cultured in type III collagen. n = 6, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. (j) Cytokine profiling of multicellular 3D cultures following GOT1 inhibition. GOT1, glutamic‐oxaloacetic transaminase 1. TME, tumor microenvironment. PDAC, pancreatic ductal adenocarcinoma.

    Article Snippet: Mono‐ and multicellular 3D cultures were established as described above and grown for 7 days and then treated with 25 μM GOT1 inhibitor (MedchemExpress HY‐122723) alone or combined with 100 nM gemcitabine (Sigma‐Aldrich G6423) and 100 nM nab‐paclitaxel (Bristol‐Myers Squibb), which were dissolved directly into PDAC or TKCC cell media.

    Techniques: Inhibition, Concentration Assay, Staining, Western Blot, Activity Assay, Cell Culture

    Analyses of cell responses following combined GOT1 inhibition and treatment with cytotoxic drugs. (a) Schematic of experimental rationale. (b) Cell viability of mono‐ and multicellular 3D cultures grown in GelMA‐HAMA hydrogels following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, *** = p ≤ 0.001. (c) Gene ontology enrichment analysis, (d) signaling pathway analysis, and (e) volcano plot showing significantly up/downregulated matrisome proteins of treated multicellular 3D cultures compared to non‐treated cells grown in GelMA‐HAMA hydrogels. Blue = upregulated, red = downregulated. (f) Relative metabolite quantification in multicellular 3D cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Journal: Advanced Science

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    doi: 10.1002/advs.202516578

    Figure Lengend Snippet: Analyses of cell responses following combined GOT1 inhibition and treatment with cytotoxic drugs. (a) Schematic of experimental rationale. (b) Cell viability of mono‐ and multicellular 3D cultures grown in GelMA‐HAMA hydrogels following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, *** = p ≤ 0.001. (c) Gene ontology enrichment analysis, (d) signaling pathway analysis, and (e) volcano plot showing significantly up/downregulated matrisome proteins of treated multicellular 3D cultures compared to non‐treated cells grown in GelMA‐HAMA hydrogels. Blue = upregulated, red = downregulated. (f) Relative metabolite quantification in multicellular 3D cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. FDR cut‐off = 0.05, log2(fold‐change) ≥ 2. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Article Snippet: Mono‐ and multicellular 3D cultures were established as described above and grown for 7 days and then treated with 25 μM GOT1 inhibitor (MedchemExpress HY‐122723) alone or combined with 100 nM gemcitabine (Sigma‐Aldrich G6423) and 100 nM nab‐paclitaxel (Bristol‐Myers Squibb), which were dissolved directly into PDAC or TKCC cell media.

    Techniques: Inhibition

    Multicellular 3D cultures including patient‐derived PDAC cells and their response toward GOT1 inhibition. (a) Micrograph of multicellular 3D cultures grown in GelMA‐HAMA hydrogels (scale bar = 100 µm). (b) Cell metabolic activity and (c) DNA content of mono‐ and multicellular 3D cultures including patient‐derived PDAC cells in GelMA‐HAMA hydrogels. (d) Cell viability, and (e) DNA content of mono‐ and multicellular TKCC‐22‐LO cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. (f) Live/dead staining (scale bar = 100 µm), and (g) heatmap of amino acid metabolism microarray of multicellular 3D cultures treated with the GOT1 inhibitor compared to non‐treated cells. PDAC, pancreatic ductal adenocarcinoma. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Journal: Advanced Science

    Article Title: GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer

    doi: 10.1002/advs.202516578

    Figure Lengend Snippet: Multicellular 3D cultures including patient‐derived PDAC cells and their response toward GOT1 inhibition. (a) Micrograph of multicellular 3D cultures grown in GelMA‐HAMA hydrogels (scale bar = 100 µm). (b) Cell metabolic activity and (c) DNA content of mono‐ and multicellular 3D cultures including patient‐derived PDAC cells in GelMA‐HAMA hydrogels. (d) Cell viability, and (e) DNA content of mono‐ and multicellular TKCC‐22‐LO cultures following treatment with GOT1 inhibitor ± gemcitabine and nab‐paclitaxel. n = 3, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 0.0001. (f) Live/dead staining (scale bar = 100 µm), and (g) heatmap of amino acid metabolism microarray of multicellular 3D cultures treated with the GOT1 inhibitor compared to non‐treated cells. PDAC, pancreatic ductal adenocarcinoma. GOT1, glutamic‐oxaloacetic transaminase 1. GelMA, gelatin methacrylate. HAMA, hyaluronic acid methacrylate.

    Article Snippet: Mono‐ and multicellular 3D cultures were established as described above and grown for 7 days and then treated with 25 μM GOT1 inhibitor (MedchemExpress HY‐122723) alone or combined with 100 nM gemcitabine (Sigma‐Aldrich G6423) and 100 nM nab‐paclitaxel (Bristol‐Myers Squibb), which were dissolved directly into PDAC or TKCC cell media.

    Techniques: Derivative Assay, Inhibition, Activity Assay, Staining, Microarray

    TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes (GOT1, GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)

    Journal: Journal of Translational Medicine

    Article Title: FFAR4 negatively regulates colorectal cancer growth via blocking oxidative phosphorylation

    doi: 10.1186/s12967-026-07942-4

    Figure Lengend Snippet: TUG891 reduces the NAD⁺/NADH ratio and disrupts mitochondrial redox homeostasis. ( A - B ) Principal-component analysis (PCA) of gene expression data, showing the clustering of gene profiles for control and FFAR4 activation groups in HCT116 cells ( A ) and HT29 cells ( B ). ( C ) Changes in metabolite levels with and without TUG891 treatment in HCT116 cells (upper panel) and HT29 cells (lower panel). Log2(FC) indicates log2-transformed fold change of the TUG891-treated group relative to the control group. ( D - E ) Over-Representation Analysis identified significantly enriched KEGG pathways based on different metabolites in HCT116 cells ( D ) and HT29 cells ( E ). ( F ) Western blot analysis of malate–aspartate shuttle–related enzymes (GOT1, GOT2, MDH1, and MDH2) and OXPHOS proteins in control and TUG891-treated cells. ( G - H ) Measurement of NAD + levels and the NAD + /NADH ratio in HCT116 cells comparing vehicle and FFAR4 activator groups. ( I - J ) Measurement of NAD + levels and the NAD + /NADH ratio in HT29 cells comparing vehicle and FFAR4 activator groups. ( K , L ) Measurement of the cellular ATP/ADP ratio in HCT116 ( K ) and HT29 ( L ) cells comparing vehicle and FFAR4 activator–treated groups. The data were expressed as the mean ± standard deviation (SD)

    Article Snippet: The primary antibodies included Cyclin D1 (Proteintech, China), GOT1 (ABclonal, China), GOT2 (ABclonal, China), MDH1 (ABclonal, China), MDH2 (ABclonal, China), OXPHOS Cocktail (Proteintech, China), and β-actin (Cell Signaling Technology, USA), all diluted 1:1000 in TBST containing 3% bovine serum albumin (BSA).

    Techniques: Gene Expression, Control, Activation Assay, Transformation Assay, Western Blot, Standard Deviation

    TUG891 suppresses tumor growth in an MC38 syngeneic mouse model. ( A ) Body weight of mice treated with PBS or TUG891 during the experimental period ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( B ) Tumor growth curves showing tumor volume over time ( n = 7). The data were expressed as the mean ± Error of the Mean (SEM). ( C ) Representative images of excised tumors at the experimental endpoint ( n = 7). ( D ) Tumor weights measured at sacrifice ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( E ) Immunofluorescence staining of FFAR4 in tumor tissues from PBS- and TUG891-treated mice. ( F ) Western blot analysis of GOT1, MDH1, and oxidative phosphorylation–related proteins (ATP5A1 and UQCRC1) in tumor tissues. ns, not significant ( P ≥ 0.05)

    Journal: Journal of Translational Medicine

    Article Title: FFAR4 negatively regulates colorectal cancer growth via blocking oxidative phosphorylation

    doi: 10.1186/s12967-026-07942-4

    Figure Lengend Snippet: TUG891 suppresses tumor growth in an MC38 syngeneic mouse model. ( A ) Body weight of mice treated with PBS or TUG891 during the experimental period ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( B ) Tumor growth curves showing tumor volume over time ( n = 7). The data were expressed as the mean ± Error of the Mean (SEM). ( C ) Representative images of excised tumors at the experimental endpoint ( n = 7). ( D ) Tumor weights measured at sacrifice ( n = 7). The data were expressed as the mean ± standard deviation (SD). ( E ) Immunofluorescence staining of FFAR4 in tumor tissues from PBS- and TUG891-treated mice. ( F ) Western blot analysis of GOT1, MDH1, and oxidative phosphorylation–related proteins (ATP5A1 and UQCRC1) in tumor tissues. ns, not significant ( P ≥ 0.05)

    Article Snippet: The primary antibodies included Cyclin D1 (Proteintech, China), GOT1 (ABclonal, China), GOT2 (ABclonal, China), MDH1 (ABclonal, China), MDH2 (ABclonal, China), OXPHOS Cocktail (Proteintech, China), and β-actin (Cell Signaling Technology, USA), all diluted 1:1000 in TBST containing 3% bovine serum albumin (BSA).

    Techniques: Standard Deviation, Immunofluorescence, Staining, Western Blot, Phospho-proteomics